FUZIM-250 contains Cefuroxime Axetil, a second-generation cephalosporin antibiotic that
provides broad-spectrum activity against both gram-positive and gram-negative bacteria. It is
effective in treating a wide range of bacterial infections by inhibiting bacterial cell wall synthesis.
Key Benefits:
● Broad-spectrum action against respiratory, urinary, skin, and ENT infections
● High oral bioavailability and effective systemic distribution
● Well-tolerated with a favorable safety profile
● Suitable for both adults and pediatric patients (as per physician’s guidance)
● Convenient twice-daily dosing for better compliance
Indications:
● Respiratory tract infections (e.g., bronchitis, pneumonia)
● Urinary tract infections (UTIs)
● Skin and soft tissue infections
● Ear, nose, and throat infections (e.g., sinusitis, tonsillitis)
● Lyme disease (early stage)